Multiple Sclerosis Trial, Recruiting NCT06461481 Sponsor: Heinrich-Heine University, Duesseldorf Condition: Multiple Sclerosis
Back to Multiple Sclerosis

Multiple Sclerosis Trial, Recruiting

NCT06461481
Recruiting Not Applicable

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

  • You have been diagnosed with relapsing-remitting multiple sclerosis (RRMS), confirmed using a specific set of medical guidelines called the 2017 McDonald criteria
  • You are either switching from a strong MS medication to a less intensive one, or stopping a lower-strength MS medication altogether
  • You own a smartphone (this requirement applies to the main study centre only)
  • Your level of physical disability is below a certain threshold, measured by a standard MS scale called the EDSS, with a score below 7.0 (confirm with trial site)
  • You are able to use a smartphone independently (this requirement applies to the main study centre only)

Who may not be able to join:

  • You have had a recent MS relapse or have received steroid treatment through a drip, or a blood-filtering treatment called immunoadsorption, within the last six weeks
  • You have another health condition that might make it difficult for you to understand or complete the study, such as certain mental health conditions or dementia — the trial team will make this decision on a case-by-case basis
  • You have been diagnosed with primary progressive MS or secondary progressive MS (rather than the relapsing-remitting form)

⚠️ Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 13 July 2026
This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.

Contact this trial

Principal Investigator: Marc Günter Pawlitzki, PD Dr. med., Heinrich-Heine University, Duesseldorf

Phone: +49 02118117887

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Recruiting
Phase
Not Applicable
Sponsor
Heinrich-Heine University, Duesseldorf
Registry
ClinicalTrials.gov
Start date
15 June 2024
Est. completion
30 October 2026

Where this trial is recruiting

🇩🇪 Germany

Primary endpoints

Percentage of disease activity, measured by loss of NEDA at month 24

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 13 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov